Time‐to‐event clinical trial designs: Existing evidence and remaining concerns

Abstract

AbstractWell‐designed placebo‐controlled clinical trials are critical to the development of novel treatments for epilepsy, but their design has not changed for decades. Patients, clinicians, regulators, and innovators all have concerns that recruiting for trials is challenging, in part, due to the static design of maintaining participants for long periods on add‐on placebo when there are an increasing number of options for therapy. A traditional trial maintains participants on blinded treatment for a static period (e.g., 12 weeks of maintenance), during which participants on placebo have an elevated risk of sudden unexpected death in epilepsy compared to patients on an active treatment. Time‐to‐event trials observe participants on blinded treatment until a key event occurs (e.g., post‐randomization seizure count matches pre‐randomization monthly seizure count). In this article, we review the evidence for these designs based on re‐analysis of prior trials, one published trial that used a time‐to‐second seizure design, and experience from an ongoing blinded trial. We also discuss remaining concerns regarding time‐to‐event trials. We conclude that, despite potential limitations, time‐to‐event trials are a potential promising mechanism to make trials more patient friendly and reduce placebo exposure, which are urgent needs to improve safety and increase recruitment to trials.